Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single Dose Pharmacokinetics of Doravirine in HIV-infected Pregnant Women
NCT04900974Phase 1Completed
- Sponsor
- University of North Carolina at Chapel Hill
- Start
- Jun 2022
- Primary completion
- Mar 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of doravirine in human immunodeficiency virus infection (HIV), sponsored by University of North Carolina at Chapel Hill. Primary endpoints: Maximum Observed Plasma Concentration at 72 hours, Time to Reach Maximum Observed Plasma Concentration at 72 hours and 3 more. Started Jun 2022; status: completed.
02
Drugs
doravirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04900974.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04900974.